Publications for Olle Stål
Co-author map based on ISI articles 2007-

Publications mentioned in social media 48 times*

Keywords

tumors treatment tamoxifen survival risk recurrence receptor randomized protein prognostic patients hoxb13 gene clinical cells cancer breast benefit adjuvant (hr

Journal Articles

Sophie Lehn, Nicholas P. Tobin, Andrew H. Sims, Olle Stål, Karin Jirstrom, Hakan Axelson and Goran Landberg
  Decreased expression of Yes-associated protein is associated with outcome in the luminal A breast cancer subgroup and with an impaired tamoxifen response
  BMC Cancer, 2014, 14(119), .
   Fulltext  PDF  
 Web of Science® Times Cited: 1

Erik Hilborn, Tove Sivik, Tommy Fornander, Olle Stål, Bo Nordenskjöld and Agneta Jansson
  C-X-C ligand 10 and C-X-C receptor 3 status can predict tamoxifen treatment response in breast cancer patients
  Breast Cancer Research and Treatment, 2014, 145(1), 73-82.

Martin Sjostrom, Linda Hartman, Dorthe Grabau, Tommy Fornander, Per Malmstrom, Bo Nordenskjöld, Dennis C. Sgroi, Lambert Skoog, Olle Stål, L.M. Fredrik Leeb-Lundberg and Marten Ferno
  Lack of G protein-coupled estrogen receptor (GPER) in the plasma membrane is associated with excellent long-term prognosis in breast cancer
 
Altmetric usage: 1

  Breast Cancer Research and Treatment, 2014, 145(1), 61-71.

Helena Aguilar, Ander Urruticoechea, Pasi Halonen, Kazuma Kiyotani, Taisei Mushiroda, Xavier Barril, Jordi Serra-Musach, Abul Islam, Livia Caizzi, Luciano Di Croce, Ekaterina Nevedomskaya, Wilbert Zwart, Josefine Bostner, Elin Karlsson, Gizeh Perez-Tenorio, Tommy Fornander, Dennis C Sgroi, Rafael Garcia-Mata, Maurice Phm Jansen, Nadia García, Núria Bonifaci, Fina Climent, María Teresa Soler, Alejo Rodríguez-Vida, Miguel Gil, Joan Brunet, Griselda Martrat, Laia Gómez-Baldó, Ana I Extremera, Agnes Figueras, Josep Balart, Robert Clarke, Kerry L Burnstein, Kathryn E Carlson, John A Katzenellenbogen, Miguel Vizoso, Manel Esteller, Alberto Villanueva, Ana B Rodríguez-Peña, Xosé R Bustelo, Yusuke Nakamura, Hitoshi Zembutsu, Olle Stål, Roderick L Beijersbergen and Miguel Angel Pujana
  VAV3 mediates resistance to breast cancer endocrine therapy
 
Altmetric usage: 6

  Breast Cancer Research, 2014, 16(3), R53.

Henrik J. Johansson, Betzabe C. Sanchez, Filip Mundt, Jenny Forshed, Aniko Kovacs, Elena Panizza, Lina Hultin-Rosenberg, Bo Lundgren, Ulf Martens, Gyongyver Mathe, Zohar Yakhini, Khalil Helou, Kamilla Krawiec, Lena Kanter, Anders Hjerpe, Olle Stål, Barbro K. Linderholm and Janne Lehtio
  Retinoic acid receptor alpha is associated with tamoxifen resistance in breast cancer
 
Altmetric usage: 11

  Nature Communications, 2013, 4(3175), .
 Web of Science® Times Cited: 3

Dorthe Aamand Grabau, Par-Ola Bendahl, Lisa Ryden, Olle Stål and Marten Ferno
  The prevalence of immunohistochemically determined oestrogen receptor positivity in primary breast cancer is dependent on the choice of antibody and method of heat-induced epitope retrieval - prognostic implications?
  Acta Oncologica, 2013, 52(8), 1657-1666.

B K. Linderholm, S Linder, Lars-Gunnar Arnesson and Olle Stål
  Identification of intermediate risk breast cancer patients with1-3 positive lymph nodes and excellent survival after tamoxifen as only systemic adjuvant therapy by use of markers of proliferation and apoptosis
  Breast, 2013, 22(5), 643-649.

Ivan Shabo, Hans Olsson, Olle Stål and Joar Svanvik
  Breast Cancer Expression of DAP12 is Associated With Skeletal and Liver Metastases and Poor Survival
  Clinical Breast Cancer, 2013, 13(5), 371-377.
 Web of Science® Times Cited: 3

M. Weiner, L Skoog, T Fornander, Bo Nordenskjöld, D C. Sgroi and Olle Stål
  Oestrogen receptor co-activator AIB1 is a marker of tamoxifen benefit in postmenopausal breast cancer
 
Altmetric usage: 9

  Annals of Oncology, 2013, 24(8), 1994-1999.
   Fulltext  PDF  

Yi Zhang, Catherine A. Schnabel, Brock E. Schroeder, Piiha-Lotta Jerevall, Rachel C. Jankowitz, Tommy Fornander, Olle Stål, Adam M. Brufsky, Dennis Sgroi and Mark G. Erlander
  Breast Cancer Index Identifies Early-Stage Estrogen Receptor-Positive Breast Cancer Patients at Risk for Early- and Late-Distant Recurrence
 
Altmetric usage: 10

  Clinical Cancer Research, 2013, 19(15), 4196-4205.
 Web of Science® Times Cited: 7

Anna Gothlin Eremo, Pia Wegman, Olle Stål, Bo Nordenskjöld, Tommy Fornander and Sten Wingren
  Wwox expression may predict benefit from adjuvant tamoxifen in randomized breast cancer patients
  Oncology Reports, 2013, 29(4), 1467-1474.
 Web of Science® Times Cited: 2

Linda Bojmar, Elin Karlsson, Sander Ellegard, Hans Olsson, Bergthor Björnsson, Olof Hallböök, Marie Larsson, Olle Stål and Per Sandström
  The Role of MicroRNA-200 in Progression of Human Colorectal and Breast Cancer
 
Altmetric usage: 3

  PLoS ONE, 2013, 8(12), 84815.
   Fulltext  PDF  
 Web of Science® Times Cited: 1

Helena Fohlin, Gizeh Perez-Tenorio, Tommy Fornander, Lambert Skoog, Bo Nordenskjöld, John Carstensen and Olle Stål
  Akt2 expression is associated with good long-term prognosis in oestrogen receptor positive breast cancer
 
Altmetric usage: 1

  European Journal of Cancer, 2013, 49(6), 1196-1204.
   Fulltext  PDF  
 Web of Science® Times Cited: 1

Johan Rosell, Bo Nordenskjöld, Nils-Olof Bengtsson, Tommy Fornander, Thomas Hatschek, Henrik Lindman, Per-Olof Malmstrom, Arne Wallgren, Olle Stål and John Carstensen
  Effects of adjuvant tamoxifen therapy on cardiac disease: results from a randomized trial with long-term follow-up
 
Altmetric usage: 2

  Breast Cancer Research and Treatment, 2013, 138(2), 467-473.
 Web of Science® Times Cited: 1

C. Strand, M. Bak, S. Borgquist, G. Chebil, A.-K. Falck, M.-L. Fjallskog, D. Grabau, I. Hedenfalk, K. Jirstrom, M. Klintman, P. Malmstrom, Hans Olsson, L. Ryden, Olle Stål, P.-O. Bendahl and M. Ferno
  The combination of Ki67, histological grade and estrogen receptor status identifies a low-risk group among 1,854 chemo-naïve women with N0/N1 primary breast cancer
 
Altmetric usage: 1

  SpringerPlus, 2013, 2(1), 1-10.

Elin Karlsson, Gizeh Pérez-Tenorio, Risul Amin, Josefine Bostner, Lambert Skoog, Tommy Fornander, Dennis C Sgroi, Bo Nordenskjöld, Anna-Lotta Hallbeck and Olle Stål
  The mTOR effectors 4EBP1 and S6K2 are frequently coexpressed, and associated with a poor prognosis and endocrine resistance in breast cancer: a retrospective study including patients from the randomised Stockholm tamoxifen trials.
 
Altmetric usage: 2

  Breast Cancer Research, 2013, 15(5), R96.
   Fulltext  PDF  
 Web of Science® Times Cited: 3

Josefine Bostner, Elin Karlsson, Muneeswaran J. Pandiyan, Hanna Westman, Lambert Skoog, Tommy Fornander, Bo Nordenskjöld and Olle Stål
  Activation of Akt, mTOR, and the estrogen receptor as a signature to predict tamoxifen treatment benefit
  Breast Cancer Research and Treatment, 2013, 137(2), 397-406.
 Web of Science® Times Cited: 10

Karolina Holm, Dorthe Grabau, Kristina Lovgren, Steina Aradottir, Sofia Gruvberger-Saal, Jillian Howlin, Lao H Saal, Stephen P Ethier, Par-Ola Bendahl, Olle Stål, Per Malmstrom, Marten Ferno, Lisa Ryden, Cecilia Hegardt, Ake Borg and Markus Ringner
  Global H3K27 trimethylation and EZH2 abundance in breast tumor subtypes
  Molecular Oncology, 2012, 6(5), 494-506.
 Web of Science® Times Cited: 16

Susann Busch, Lisa Ryden, Olle Stål, Karin Jirstrom and Goran Landberg
  Low ERK Phosphorylation in Cancer-Associated Fibroblasts Is Associated with Tamoxifen Resistance in Pre-Menopausal Breast Cancer
 
Altmetric usage: 1

  PLoS ONE, 2012, 7(9), .
   Fulltext  PDF  
 Web of Science® Times Cited: 5

Tove Sivik, Cecilia Gunnarsson, Tommy Fornander, Bo Nordenskjöld, Lambert Skoog, Olle Stål and Agneta Jansson
  17β-hydroxysteroid dehydrogenase type 14 is a predictive marker for tamoxifen response in oestrogen receptor positive breast cancer
  PLoS ONE, 2012, 7(7), e40568.
   Fulltext  PDF  
 Web of Science® Times Cited: 1

Katja Lundgren, Nicholas P Tobin, Olle Stål, Lisa Ryden, Karin Jirstrom and Goran Landberg
  Stromal Expression of beta-Arrestin-1 Predicts Clinical Outcome and Tamoxifen Response in Breast Cancer
  Journal of Molecular Diagnostics, 2011, 13(3), 340-351.
 Web of Science® Times Cited: 4

Emelie Djerf, Cecilia Trinks, Henrik Green, Avni Abdiu, Anna-Lotta Hallbeck, Olle Stål and Thomas Walz
  The pan-ErbB receptor tyrosine kinase inhibitor canertinib promotes apoptosis of malignant melanoma in vitro and displays anti-tumor activity in vivo
  Biochemical and Biophysical Research Communications - BBRC, 2011, 414(3), 563-568.
 Web of Science® Times Cited: 2

Henrik Green, Olle Stål, K Bachmeier, L M Bäcklund, L Carlsson, J Hansen, M Lagerlund, B Norberg, A Franzén, A Åleskog and Annika Malmström
  Pegylated liposomal doxorubicin as first-line monotherapy in elderly women with locally advanced or metastatic breast cancer: Novel treatment predictive factors identified
  Cancer Letters, 2011, 313(2), 145-153.
   Fulltext  PDF  
 Web of Science® Times Cited: 4

Elin Karlsson, Marie Ahnström, Josefine Bostner, Gizeh Perez-Tenorio, Birgit Olsson, Anna-Lotta Hallbeck and Olle Stål
  High-Resolution Genomic Analysis of the 11q13 Amplicon in Breast Cancers Identifies Synergy with 8p12 Amplification, Involving the mTOR Targets S6K2 and 4EBP1
 
Altmetric usage: 1

  Genes, Chromosomes and Cancer, 2011, 50(10), 775-787.
   Fulltext  PDF  
 Web of Science® Times Cited: 12

Gizeh Perez-Tenorio, Elin Karlsson, Marie Ahnström, Birgit Olsson, Birgitta Holmlund, Bo Nordenskjöld, Tommy Fornander, Lambert Skoog and Olle Stål
  Clinical potential of the mTOR targets S6K1 and S6K2 in breast cancer
  Breast Cancer Research and Treatment, 2011, 128(3), 713-723.
   Fulltext  PDF  
 Web of Science® Times Cited: 9

Piiha-Lotta Jerevall, Xiai-Jun Ma, Hongying Li, Ranelle Salunga, Nicole C. Kesty, Mark G. Erlander, Dennis Sgroi, Birgitta Holmlund, Lambert Skoog, Tommy Fornander, Bo Nordenskjöld and Olle Stål
  Prognostic utility of HOXB13:IL17BR and Molecular Grade Index in early-stage breast cancer patients from the Stockholm trial
  British Journal of Cancer, 2011, 104(11), 1762-1769.
   Fulltext  PDF  
 Web of Science® Times Cited: 28

Pia Wegman, Anna Gothlin Eremo, Angelica Lindlof, Mats Karlsson, Olle Stål and Sten Wingren
  Expression of the forkhead transcription factor FOXL2 correlates with good prognosis in breast cancer patients treated with tamoxifen
  INTERNATIONAL JOURNAL OF ONCOLOGY, 2011, 38(4), 1145-1151.
 Web of Science® Times Cited: 1

Johan Rosell, Bo Nordenskjöld, N-O Bengtsson, T Fornander, T Hatschek, H Lindman, P-O Malmstrom, A Wallgren, Olle Stål and John Carstensen
  Time dependent effects of adjuvant tamoxifen therapy on cerebrovascular disease: results from a randomised trial
  BRITISH JOURNAL OF CANCER, 2011, 104(6), 899-902.
 Web of Science® Times Cited: 3

Mahmoud R Khoshnoud, Britta Lofdahl, Helena Fohlin, Tommy Fornander, Olle Stål, Lambert Skoog, Jonas Bergh and Bo Nordenskjöld
  Immunohistochemistry compared to cytosol assays for determination of estrogen receptor and prediction of the long-term effect of adjuvant tamoxifen
  Breast Cancer Research and Treatment, 2011, 126(2), 421-430.
 Web of Science® Times Cited: 13

Marleen Kok, Wilbert Zwart, Caroline Holm, Renske Fles, Michael Hauptmann, LauraJ. Vant Veer, Lodewyk F. A. Wessels, Jacques Neefjes, Olle Stål, Sabine C. Linn, Goran Landberg and Rob Michalides
  PKA-induced phosphorylation of ER alpha at serine 305 and high PAK1 levels is associated with sensitivity to tamoxifen in ER-positive breast cancer
  Breast Cancer Research and Treatment, 2011, 125(1), .
 Web of Science® Times Cited: 21

Maria Stendahl, Sofie Nilsson, Caroline Wigerup, Karin Jirstrom, Per Ebbe Jonsson, Olle Stål and Goran Landberg
  p27(Kip1) is a predictive factor for tamoxifen treatment response but not a prognostic marker in premenopausal breast cancer patients
  INTERNATIONAL JOURNAL OF CANCER, 2010, 127(12), 2851-2858.
 Web of Science® Times Cited: 9

Piiha-Lotta Jerevall, Agneta Jansson, Tommy Fornander, Lambert Skoog, Bo Nordenskjöld and Olle Stål
  Predictive relevance of HOXB13 protein expression for tamoxifen benefit in breast cancer
  Breast Cancer Research, 2010, 12(4), .
 Web of Science® Times Cited: 6

Josefine Bostner, Lambert Skoog, Tommy Fornander, Bo Nordenskjöld and Olle Stål
  Estrogen Receptor-alpha Phosphorylation at Serine 305, Nuclear p21-Activated Kinase 1 Expression, and Response to Tamoxifen in Postmenopausal Breast Cancer
  Clinical Cancer Research, 2010, 16(5), 1624-1633.
   Fulltext  PDF  
 Web of Science® Times Cited: 19

B. C. Sanchez, M. Sundqvist, Helena Fohlin, F. Spyratos, Bo Nordenskjöld, Olle Stål, B. K and Linderholm
  Prolonged tamoxifen treatment increases relapse-free survival for patients with primary breast cancer expressing high levels of VEGF
  European Journal of Cancer, 2010, 46(9), 1580-1587.
 Web of Science® Times Cited: 4

Ann-Christine Kallstrom, Rebecka Salme, Lisa Ryden, Bo Nordenskjöld, Per-Ebbe Jonsson and Olle Stål
  17 beta-Hydroxysteroid dehydrogenase type 1 as predictor of tamoxifen response in premenopausal breast cancer
  EUROPEAN JOURNAL OF CANCER, 2010, 46(5), 892-900.
 Web of Science® Times Cited: 5

Lisa Ryden, Karin Jirstrom, Monica Haglund, Olle Stål and Marten Ferno
  Epidermal growth factor receptor and vascular endothelial growth factor receptor 2 are specific biomarkers in triple-negative breast cancer. Results from a controlled randomized trial with long-term follow-up
  BREAST CANCER RESEARCH AND TREATMENT, 2010, 120(2), 491-498.
 Web of Science® Times Cited: 30

S Alkner, P-O Bendahl, D Grabau, K Lovgren, Olle Stål, L Ryden and M Ferno
  AIB1 is a predictive factor for tamoxifen response in premenopausal women
  ANNALS OF ONCOLOGY, 2010, 21(2), 238-244.
 Web of Science® Times Cited: 16

Marleen Kok, Caroline Holm-Wigerup, Michael Hauptmann, Rob Michalides, Olle Stål, Sabine Linn and Goran Landberg
  Estrogen Receptor-alpha Phosphorylation at Serine-118 and Tamoxifen Response in Breast Cancer
  Journal of the National Cancer Institute, 2009, 101(24), 1725-1729.
 Web of Science® Times Cited: 19

Annika Jogi, Donal J Brennan, Lisa Ryden, Kristina Magnusson, Marten Ferno, Olle Stål, Signe Borgquist, Mathias Uhlen, Goran Landberg, Sven Pahlman, Fredrik Ponten and Karin Jirstrom
  Nuclear expression of the RNA-binding protein RBM3 is associated with an improved clinical outcome in breast cancer
  MODERN PATHOLOGY, 2009, 22(12), 1564-1574.

Agneta Jansson, Lovisa Delander, Cecilia Gunnarsson, Tommy Fornander, Lambert Skoog, Bo Nordenskjöld and Olle Stål
  Ratio of 17HSD1 to 17HSD2 protein expression predicts the outcome of tamoxifen treatment in postmenopausal breast cancer patients.
  Clinical Cancer Research, 2009, 15(10), 3610-3616.
 Web of Science® Times Cited: 12

C Holm, M Kok, R Michalides, R Fles, R H T Koornstra, J Wesseling, M Hauptmann, J Neefjes, J L Peterse, Olle Stål, G Landberg and S C Linn
  Phosphorylation of the oestrogen receptor alpha at serine 305 and prediction of tamoxifen resistance in breast cancer
  JOURNAL OF PATHOLOGY, 2009, 217(3), 372-379.
 Web of Science® Times Cited: 22

Marie Ahnström, Marie Askmalm Stenmark, Bo Nordenskjöld, Tommy Fornander, Lambert Skoog and Olle Stål
  Altered expression of cyclin E and the retinoblastoma protein influences the effect of adjuvant therapy in breast cancer
  International Journal of Oncology, 2009, 34(2), 441-448.
 Web of Science® Times Cited: 6

Patrik Johansson, Helena Fohlin, Lars-Gunnar Arnesson, Monika Dufmats, Kerstin Nordenskjoeld, Bo Nordenskjöld and Olle Stål
  Improved survival for women with stage I breast cancer in south-east Sweden: A comparison between two time periods before and after increased use of adjuvant systemic therapy
  ACTA ONCOLOGICA, 2009, 48(4), 504-513.
   Fulltext  PDF  
 Web of Science® Times Cited: 2

Gizeh Perez-Tenorio, Elin Karlsson, Marie Ahnström Waltersson, Birgit Olsson, Birgitta Holmlund, Bo Nordenskjöld, Tommy Fornander, Lambert Skoog and Olle Stål
  Clinical Value of RPS6KB1 and RPS6KB2 Gene Amplification in Postmenopausal Breast Cancer
  , 2008, , .

Emma Niméus-Malmström, Morten Krogh, Per Malmström, Carina Strand, Irma Fredriksson, Per Karlsson, Bo Nordenskjöld, Olle Stål, Görel Östberg, Carsten Peterson and Marten Ferno
  Gene expression profiling in primary breast cancer distinguishes patients developing local recurrence after breast-conservation surgery, with or without postoperative radiotherapy
  Breast Cancer Research, 2008, 10(2), .
 Web of Science® Times Cited: 19

Lisa Rydén, Göran Landberg, Olle Stål, Bo Nordenskjöld, Mårten Fernö and Pär-Ola Bendahl
  HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information
  Breast Cancer Research and Treatment, 2008, 109(2), 351-357.
 Web of Science® Times Cited: 20

Ivan Shabo, Olle Stål, Hans Olsson, Siv Doré and Joar Svanvik
  Breast cancer expression of CD163, a macrophage scavenger receptor, is related to early distant recurrence and reduced patient survival
  International Journal of Cancer, 2008, 123(4), 780-786.
 Web of Science® Times Cited: 56

Cecilia Gunnarsson, Piiha-Lotta Jerevall, Karl Hammar, Birgit Olsson, Bo Nordenskjöld, Agneta Jansson and Olle Stål
  Amplification of HSD17B1 has prognostic significance in postmenopausal breast cancer
  Breast Cancer Research and Treatment, 2008, 108(1), 35-41.
 Web of Science® Times Cited: 18

Piiha-Lotta Jerevall, Sara Brommesson, Carina Strand, Sofia Gruvberger-Saal, Per Malmström, Bo Nordenskjöld, Sten Wingren, Peter Söderkvist, Mårten Fernö and Olle Stål
  Exploring the two-gene ratio in breast cancer – independent roles for HOXB13 and IL17BR in prediction of clinical outcome
  Breast Cancer Research and Treatment, 2008, 107(2), 225-234.
   Fulltext  PDF  
 Web of Science® Times Cited: 25

Gizeh Pérez-Tenorio, Liza Alkhori, Birgit Olsson, Marie Ahnstro Waltersson, Bo Nordenskjöld, Lars Erik Rutqvist, Lambert Skoog and Olle Stål
  PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer
  Clinical Cancer Research, 2007, 13(12), 3577-3584.
 Web of Science® Times Cited: 120

Agneta Jansson, Jonas Carlsson, Anette Olsson, Petter Storm, Sara Margolin, Cecilia Gunnarsson, Marie Stenmark Askmalm, Annika Lindblom, Bengt Persson and Olle Stål
  A new polymorphism in the coding region of exon four in HSD17B2 in relation to risk of sporadic and hereditary breast cancer
  Breast Cancer Research and Treatment, 2007, 106(1), 57-64.
 Web of Science® Times Cited: 6

Pia Wegman Palmebäck, Sauli Elingarami, John Carstensen, Olle Stål, Bo Nordenskjöld and Sten Wingren
  Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal breast cancer patients
  Breast Cancer Research, 2007, 9(1), R7.
   Fulltext  PDF  
 Web of Science® Times Cited: 145

Karin Söderlund Leifler, Olle ¨, Lambert Skoog, Lars Erik Rutqvist, Bo Nordenskjöld and Marie Stenmark Askmalm
  Intact Mre11/Rad50/Nbs1 complex predicts good response to radiotherapy in early breast cancer
  International Journal of Radiation Oncology, Biology, Physics, 2007, 68(1), 50-58.
 Web of Science® Times Cited: 30

Josefine Bostner, Marie Ahnström Waltersson, T Fornander, L Skoog, Bo Nordenskjöld and Olle Stål
  Amplification of CCND1 and PAK1 as predictors of recurrence and tamoxifen resistance in postmenopausal breast cancer.
  Oncogene, 2007, 26(49), 6997-7005.
 Web of Science® Times Cited: 52

Gizeh Perez-Tenorio, Fredrik Berglund, Anna Esguerra Merca, Bo Nordenskjöld, Lars Erik Rutqvist, Lambert Skoog and Olle Stål
  Cytoplasmic p21WAF1/CIP1 correlates with Akt activation and poor response to tamoxifen in breast cancer
  International Journal of Oncology, 2006, 28(5), 1031-1042.
 Web of Science® Times Cited: 23

Agneta Jansson, Cecilia Gunnarsson and Olle Stål
  Proliferative responses to altered 17β-hydroxysteroid dehydrogenase (17HSD) type 2 expression in human breast cancer cells are dependent on endogenous expression of 17HSD type 1 and the oestradiol receptors
  Endocrine-Related Cancer, 2006, 13(3), 875-884.
 Web of Science® Times Cited: 13

Qunyan Yu, Ewa Sicinska, Yan Geng, Marie Ahnström, Agnieszka Zagozdzon, Yinxin Kong, Humphrey Gardner, Hiroaki Kiyokawa, Lyndsay N Harris, Olle Stål and Piotr Sicinski
  Requirement for CDK4 kinase function in breast cancer
  Cancer Cell, 2006, 9(1), 23-32.
 Web of Science® Times Cited: 122

Caroline Holm, Suresh Rayala, Karin Jirström, Olle Stål, Rakesh Kumar and Göran Landberg
  Association between Pak1 expression and subcellular localization and tamoxifen resistance in breast cancer patients
  Journal of the National Cancer Institute, 2006, 98(10), 671-680.
 Web of Science® Times Cited: 86

Agneta Jansson, Cecilia Gunnarsson, Maja Cohen, Tove Sivik and Olle Stål
  17β-hydroxysteroid dehydrogenase 14 affects estradiol levels in breast cancer cells and is a prognostic marker in estrogen receptor-positive breast cancer
  Cancer Research, 2006, 66(23), 11471-11477.
 Web of Science® Times Cited: 32

Cecilia Gunnarsson, Agneta Jansson, Birgitta Holmlund, Lilianne Ferraud, Bo Nordenskjöld, Lars Erik Rutqvist, Lambert Skoog and Olle Stål
  Expression of COX-2 and steroid converting enzymes in breast cancer
  Oncology Reports, 2006, 16(2), 219-224.
 Web of Science® Times Cited: 7

Pia Wegman (Palmebäck), Olle Stål, Marie Stenmark Askmalm, Bo Nordenskjöld, Lars-Erik Rutqvist and Sten Wingren
  p53 polymorphic variants at codon 72 and the outcome of therapy in randomized breast cancer patients
  Pharmacogenetics and Genomics, 2006, 16(5), 347-351.
 Web of Science® Times Cited: 14

L Ryden, K Jirstrom, PA Bendahl, M Ferno, Bo Nordenskjöld, Olle Stål, Sten Thorstenson, PE Jonsson and G Landberg
  Tumor-specific expression of vascular endothelial growth factor receptor 2 but not vascular endothelial growth factor or human epidermal growth factor receptor 2 is associated with impaired response to adjuvant tamoxifen in premenopausal breast cancer
  Journal of Clinical Oncology, 2005, 23(21), 4695-4704.
 Web of Science® Times Cited: 53

K Jirström, L Rydén, L Anagnostaki, Bo Nordenskjöld, Olle Stål, S Thorstenson, G Chebil, P-E Jönsson, M Fernö and G Landberg
  Pathology parameters and adjuvant tamoxifen response in a randomised premenopausal breast cancer trial
  Journal of Clinical Pathology, 2005, 58(11), 1135-1142.
 Web of Science® Times Cited: 26

Piiha-Lotta Jerevall, Ahmad Ahmadi, Malin Bergman, Olle Stål and Sten Wingren
  Sulfotransferase1A1 and risk of postmenopausal breast cancer
  Anticancer Research, 2005, 25(3 C), 2515-2517.
 Web of Science® Times Cited: 9

Karin Jirström, Maria Stendahl, Lisa Rydén, Åsa Kronblad, Pär-Ola Bendahl, Olle Stål and Göran Landberg
  Adverse effect of adjuvant tamoxifen in premenopausal breast cancer with cyclin D1 gene amplification
  Cancer Research, 2005, 65(17), 8009-8016.
 Web of Science® Times Cited: 61

Lisa Rydén, Per-Ebbe Jönsson, Gunilla Chebil, Monika Dufmats, Mårten Fernö, Karin Jirström, Ann-Christine Källström, Göran Landberg, Olle Stål, Sten Thorstenson and Bo Nordenskjöld
  Two years of adjuvant tamoxifen in premenopausal patients with breast cancer: a randomised, controlled trial with long-term follow-up
  European Journal of Cancer, 2005, 41(2), 256-264.
 Web of Science® Times Cited: 54

Cecilia Gunnarsson, Eva Hellqvist and Olle Stål
  17β-hydroxysteroid dehydrogenases involved in local oestrogen synthesis have prognostic significance in breast cancer
  British Journal of Cancer, 2005, 92(3), 547-552.
 Web of Science® Times Cited: 54

Pia Wegman (Palmebäck), Linda Vainikka, Olle Stål, Bo Nordenskjöld, Lambert Skoog, Lars-Erik Rutqvist and Sten Wingren
  Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients
  Breast Cancer Research, 2005, 7(3), R284-R290.
   Fulltext  PDF  
 Web of Science® Times Cited: 120

Karin Söderlund Leifler, Gizeh Pérez-Tenorio and Olle Stål
  Activation of the phosphatidylinositol 3-kinase/Akt pathway prevents radiation-induced apoptosis in breast cancer cells
  International Journal of Oncology, 2005, 26(1), 25-32.
 Web of Science® Times Cited: 29

Marie Ahnström Waltersson, Bo Nordenskjöld, Lars Erik Rutqvist, Lambert Skoog and Olle Stål
  Role of cyclin D1 in ErbB2-positive breast cancer and tamoxifen resistance.
  Breast Cancer Research and Treatment, 2005, 91(2), 145-151.
 Web of Science® Times Cited: 21

Amir Reza Razavi, Hans Gill, Olle Stål, Marie Sundquist, Sten Thorstenson, Hans Åhlfeldt, Nosrat Shahsavar and The South-East Swedish Breast Cancer Study Group
  Exploring cancer register data to find risk factors for recurrence of breast cancer: Application of Canonical Correlation Analysis
  BMC Medical Informatics and Decision Making, 2005, 5(29), 29-35.
   Fulltext  PDF  

Marie Stenmark Askmalm, John Carstensen, Bo Nordenskjöld, Birgit Olsson, Lars Erik Rutqvist, Lambert Skoog and Olle Stål
  Mutation and accumulation of p53 related to results of adjuvant therapy of postmenopausal breast cancer patients
  Acta Oncologica, 2004, 43(3), 235-244.
 Web of Science® Times Cited: 13

Olle Stål, Gizeh Perez-Tenorio, Lind Åkerberg, Birgit Olsson, Bo Nordenskjöld, Lambert Skoog and Lars Rutqvist
  Akt kinases in breast cancer and the results of adjuvant therapy
  Breast Cancer Research, 2003, 5(2), R37-R44.
 Web of Science® Times Cited: 98

Bo Baldetorp, Pär-Ola Bendahl, Mårten Ferno and Olle Stål
  Improved DNA flow cytometric, DNA ploidy, and S-phase reproducibility between 15 laboratories in analysis of breast cancer using generalized guidelines
  Cytometry, 2003, 56A(1), 1-7.
 Web of Science® Times Cited: 7

Cecilia Gunnarsson, Marie Ahnström, Kristina Kirschner, Birgit Olsson, Bo Nordenskjöld, Lars Erik Rutqvist, Lambert Skoog and Olle Stål
  Amplification of HSD17B1 and ERBB2 in primary breast cancer
  Oncogene, 2003, 22(1), 34-40.
 Web of Science® Times Cited: 53

Gizeh Pérez-Tenorio, Olle Stål and Members of the Southeast Sweden Breast Cancer Group
  Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients
  British Journal of Cancer, 2002, 86(4), 540-545.
 Web of Science® Times Cited: 244

CB Bagwell, GM Clark, A Chassevent, PO Bendahl, Olle Stål, D Killander, ML Jourdan, S Romain, B Hunsberger, S Wright and B Baldetorp
  DNA and cell cycle analysis as prognostic indicators in breast tumors revisited
  Clinics in Laboratory Medicine, 2001, 21(4), 875-+.
 Web of Science® Times Cited: 11

CB Bagwell, GM Clark, F Spyratos, A Chassevent, PO Bendahl, Olle Stål, D Killander, ML Jourdan, S Romain, B Hunsberger and B Baldetorp
  Optimizing flow cytometric DNA ploidy and S-phase fraction as independent prognostic markers for node-negative breast cancer specimens
  Cytometry, 2001, 46(3), 121-135.
 Web of Science® Times Cited: 31

Askmalm Marie Stenmark-Askmalm, Massimiliano Gentile, Sten Wingren, Olle Stål and Lars-Gunnar Arnesson
  Protein accumulation and gene mutation of p53 in bilateral breast cancer
  Acta Oncologica, 2001, 40(1), 56-62.
 Web of Science® Times Cited: 8

Cecilia Gunnarsson, Birgit Olsson, Olle Stål and Lars-Gunnar Arnesson
  Abnormal expression of 17β-hydroxysteroid dehydrogenases in breast cancer predicts late recurrence
  Cancer Research, 2001, 61(23), 8448-8451.
 Web of Science® Times Cited: 72

Gunnar Adell, Hong Zhang, Agneta Jansson, Xiao-Feng Sun, Olle Stål and Bo Nordenskjöld
  Decreased tumor cell proliferation as an indicator of the effect of preoperative radiotherapy of rectal cancer
  International Journal of Radiation Oncology, Biology, Physics, 2001, 50(3), 659-663.
 Web of Science® Times Cited: 30

Gunnar C. E. Adell, Hong Zhang, Sofia Evertsson, Xiao-Feng Sun, Olle Stål and Bo Nordenskjöld
  Apoptosis in rectal carcinoma: Prognosis and recurrence after preoperative radiotherapy
  Cancer, 2001, 91(10), 1870-1875.
 Web of Science® Times Cited: 32

Marie Sundquist, Sten Thorstenson, Lars Brudin, Olle Stål and Bo Nordenskjöld
  A comparison between flow cytometric assessment of S-phase fraction and Nottingham histologic grade as prognostic instruments in breast cancer
  Breast Cancer Research and Treatment, 2000, 63(1), 11-15.
 Web of Science® Times Cited: 5

Olle Stål, Å Borg, M Fernö, Ann-Christine Källström, P Malmström and Bo Nordenskjöld
  ErbB2 status and the benefit from two or five years of adjuvant tamoxifen in postmenopausal early stage breast cancer
  Annals of Oncology, 2000, 11(12), 1545-1550.
 Web of Science® Times Cited: 57

Mårten Fernö, Olle Stål, Bo Baldetorp, Thomas Hatschek, Ann-Christine Källström, Per Malmström, Bo Nordenskjöld and Stefan Rydén
  Results of two or five years of adjuvant tamoxifen correlated to steroid receptor and S-phase levels
  Breast Cancer Research and Treatment, 2000, 59(1), 69-76.
 Web of Science® Times Cited: 48

Måns Agrup, Olle Stål, Karen Olsen and Sten Wingren
  C-erbB-2 overexpression and survival in early onset breast cancer
  Breast Cancer Research and Treatment, 2000, 63(1), 23-29.
 Web of Science® Times Cited: 36

P Holmqvist, M Lundström and Olle Stål
  Apoptosis and Bcl-2 expression in relation to age, tumor characteristics and prognosis in breast cancer
  International Journal of Biological Markers, 1999, 14(2), 84-91.

B Vitak, K E Olsen, Jan-Christer Månson, Lars-Gunnar Arnesson and Olle Stål
  Tumour characteristics and survival in patients with invasive interval breast cancer classified according to mammographic findings at the latest screening: a comparison of true interval and missed interval cancers
  European Radiology, 1999, 9(3), 460-469.

Gunnar Adell, Xiao-Feng Sun, Olle Stål, Claes Klintenberg, Rune Sjödahl and Bo Nordenskjöld
  p53 status: an indicator for the effect of preoperative radiotherapy of rectal cancer.
  Radiotherapy and Oncology, 1999, 51(2), 169-174.

René Blom, C. Guerrieri, Olle Stål, Helena Malmström and E. Simonsen
  Leiomyosarcoma of the uterus: A clinicopathologic, DNA flow cytometric, p53, and mdm-2 analysis of 49 cases
  Gynecologic Oncology, 1998, 68(1), 54-61.

René Blom, C. Guerrieri, Olle Stål, Helena Malmström, S. Sullivan and E. Simonsen
  Malignant mixed Mullerian tumors of the uterus: a clinicopathologic, DNA flow cytometric, p53, and mdm-2 analysis of 44 cases
  Gynecologic Oncology, 1998, 68(1), 18-24.

Conference Articles

M Sundquist, E Holmberg, S Holmberg, A Kovacs, G Mathe, Olle Stål and Göran Tejler
  Assessments of Proliferation in Breast Cancer in EUROPEAN JOURNAL OF CANCER, vol 47, issue , pp S333-S333
  EUROPEAN JOURNAL OF CANCER, 2011.


Piiha-Lotta Jerevall, A. Jansson, T. Fornander, L. Skoog, Bo Nordenskjöld and Olle Stål
  HOXB13 protein expression predicts the benefit of tamoxifen treatment in breast cancer patients: in CANCER RESEARCH, vol 69, issue 2, Supplement 1, pp 358S-358S
  CANCER RESEARCH, 2009.


Olle Stål, Piiha-Lotta Jerevall, Xiai-Jun Ma, Hongying Li, Ranelle Salunga, Mark Erlander, Dennis Sgroi, Birgitta Holmlund, Lambert Skoog and Tommy Fornander
  Validation of Prognostic Utility of HOXB13:IL17BR and Molecular Grade Index in Early Stage Breast Cancer: in CANCER RESEARCH, vol 69, issue 24, pp 504S-504S
  32nd Annual CTRC-AACR San Antonio Breast Cancer Symposium. December 10, San Diego, 2009.


 Web of Science® Times Cited: 2

Tove Sivik, Olle Stål, T Fornander, L Skoog, Bo Nordenskjöld and Agneta Jansson
  Significance of 17bHSD Type 14 as a Predictive Factor for Adjuvant Tamoxifen Treatment Response in Breast Cancer in CANCER RESEARCH, vol 69, issue 24, pp 596S-597S
  CANCER RESEARCH, 2009.


MA Waltersson, E Karlsson, Bo Nordenskjöld, T Fornander, L Skoog and Olle Stål
  miR-206 Expression Is Downregulated in Cyclin D1 Amplified Breast Tumours. in CANCER RESEARCH, vol 69, issue 24, pp 579S-579S
  CANCER RESEARCH, 2009.


Josefine Bostner, T Fornander, L Skoog, Bo Nordenskjöld and Olle Stal
  Estrogen Receptor alpha Phosphorylation on Serine 305, p21-Activated Kinase 1 and Tamoxifen Response in Postmenopausal Breast Cancer in CANCER RESEARCH, vol 69, issue 24, pp 596S-596S
  CANCER RESEARCH, 2009.


E Karlsson, M A Waltersson, Josefine Bostner, Gizeh Perez-Tenorio, Birgit Olsson, T Fornander and Olle Stål
  Comprehensive Genomic and Transcriptomic Analysis of the 11q13 Amplicon in Breast Cancer in CANCER RESEARCH, vol 69, issue 24, pp 820S-821S
  CANCER RESEARCH, 2009.


B Chavez Sanchez, M Sundqvist, Olle Stål and B Linderholm
  PROLONGED TAMOXIFEN TREATMENT INCREASES SURVIVAL FOR PATIENTS WITH PRIMARY BREAST CANCERS EXPRESSING HIGH LEVELS OF VEGF
  in ANNALS OF ONCOLOGY, vol 20, 2009.


T W Miller, M Perez-Torres, H Wu, Y Shyr, M Guix, A Jiang, Olle Stål and C L Arteaga
  Loss of PTEN engages ErbB3 and IGF-I receptor signaling to promote antiestrogen resistance in breast cancer.
  CANCER RESEARCH ISSN 0008-5472: Volume 69 Issue 2, 2009.


CB Bagwell, GM Clark, F Spyratos, A Chassevent, PO Bendahl, Olle Stål, D Killander, ML Jourdan, S Romain, CB Hunsberger, S Wright and B Baldetorp
  Multivariate analyses of flow cytometric S-phase and ploidy as node-negative breast cancer prognostic factors: an international and multi-center study
  Abstract Issue, 24th Annual San Antonio, Breast Cancer Symposium. December 10-13, 2001 San Antonio Marriott Rivercenter, Texas, USA.: Breast Cancer Research and Treatment, ISSN 0167-6806, Vol 69, Issue 3, 2001.


Ph.D. Theses

Elin Karlsson
  Clinical potential of the mTOR effectors S6K1, S6K2 and 4EBP1 in breast cancer
  2014.


  Fulltext PDF

Josefine Bostner
  The Akt/mTOR Pathway and Estrogen Receptor Phosphorylations: a crosstalk with potential to predict tamoxifen resistance in breast cancer
  2013.


  Fulltext PDF

Emelie Severinsson
  Experimental studies on ErbB targeted therapy in malignant melanoma
  2012.


  Fulltext PDF

Tove Sivik
  Elucidating the role of 17β hydroxysteroid dehydrogenase type 14 in normal physiology and in breast cancer
  2012.


  Fulltext PDF

Piiha-Lotta Jerevall
  Homeobox B13 in breast cancer: Prediction of tamoxifen benefit
  2011.


  Fulltext PDF

Karin Söderlund Leifler
  DNA repair pathways and the effect of radiotherapy in breast cancer
  2009.


  Fulltext PDF

Marie Ahnström Waltersson
  Cell cycle alterations and 11q13 amplification in breast cancer: prediction of adjuvant treatment response
  2009.


  Fulltext PDF

Gizeh Pérez-Tenorio
  Alterations in the PI3K/AKT Signaling Pathway and Response to Adjuvant Treatment in Breast Cancer
  2008.


  Fulltext PDF

René Blom
  Sarcoma of the female genital tract: Histopathology, DNA cytometry, p53 and mdm-2 analysis related to prognosis
  1999.


  Fulltext PDF

Olle Stål  Static and flow cytometry for tumor DNA analysis
  1989.


Licentiate Theses

Emelie Djerf
  Studies on the effect of ErbB tyrosine kinase inhibitors on malignant melanoma growth and survival in vitro
  2009.


  Fulltext PDF

* Social media data based on publications from 2011 to present and with a DOI; data delivered by Altmetric.com.